COMPANY PROFILE
WUHAN GENERAL GROUP INC.
SYMBOL : WUHN
SECTOR : PSYCH.
O/S : 43 M
MARKET CAP : $ 8 M
MARKET OPPORTUNITY : UP TO $350 B
WUHAN GENERAL GROUP INC. is the MOST UNDERVALUED company in the psychedelic market being one of the only companies in the world to have already carried out an in vitro / in vivo study with psilocybin in animals
Wuhan General Group, Inc. through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company that researches, develops and commercializes a range of CBD-based products under Dr. AnnaRx™ and Medspresso™ brands.
In addition, its new wholly-owned division, M2Bio is researching and developing indications for psilocybin new therapies that will help patients who suffer from addiction, mental illness, Alzheimer’s and Parkinson’s. Our mission is to advance botanical-based medicine to the forefront by deploying best practice science and medicine, clinical research and emerging technologies
MAJOR DEVELOPMENT
WUHAN GENERAL GROUP INC. is currently in Pre-enrolment Patient- screening for Phase 1 Human trial.
VERY SMALL FLOAT
WUHAN GENERAL GROUP INC. O/S is ONLY 43 millions with a small float of 10 millions
COMPANY BRIEF
| Researching and developing indications for psilocybin new therapies
| Researches, develops and commercializes a range of CBD-based products under the Dr. AnnaRx and Medspresso brands
| Currently in Pre-enrolment Patient- screening for Phase 1 Human trial.
| Cosmetics and FSMP company with cannabinoid and psilocybin research, formulation and delivery system divisions
HIGHLIGHTS
| First in market to research psilocybin for treatment of alcoholism and cardiovascular tissue
| Established distribution channels in the US, Canada, Europe and Africa
| Early stage entry into cannabinoid and psilocybin company- Enormous upside
| Research undiscovered properties of cannabinoids for treatment of respiratory infectious diseases
M2BIO DEVELOPMENT
WUHAN infused beverages MEDSPRESSO
WUHAN Cosmetics and food name Dr. AnnaRx
WUHAN COMPARABLE
RVV | OTC
COMPANY INFORMATION
JOIN FACEBOOK INVESTOR GROUP
Wuhan last news | article
M2Bio Sciences, Inc (Wuhan General Group) Signs LOI With Jugular for CBD Functional Foods | WUHN
M2Bio Sciences, Inc | WUHN on OTC (Formely Wuhan General Group) MONTREAL, QC / ACCESSWIRE / July 1, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a…
M2Bio Sciences inc, an opportunity of a lifetime?
M2Bio Sciences, Inc | WUHN on OTC (Formely Wuhan General Group) In a stock market that assesses companies according to their potential and the related market. A small penny stock,…
Psychedelic highlights | June 22-26
The week of June 22-26 was again filled with amazing news in the psychedelic market M2Bio Sciences, Inc | WUHN After changing the name of the company last week to…
Wuhan General Group Signs Manufacturing, Distribution and Sales Agreement with Cafféluxe for local and international distribution of Medspresso™
WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) VISIT WUHN PROFILE HERE MONTREAL, QC / ACCESSWIRE / June 24, 2020, / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical…
Psychedelic highlights | June 15-19
Another big week in the psychedelic market. Here is what caught the attention of investors during the week of June 15-19. Champignon Brands Inc | SHRM After announcing that its…
Wuhan General Group Announces Name Change and Rebranding to M2Bio Sciences
M2Bio Sciences, Inc | MMBS MONTREAL, QC / ACCESSWIRE / June 18, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“Wuhan” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin…